Center-Authored Papers

Filters: Author is Hortobagyi, Gabriel N  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
B
Budd GT, Barlow WE, Moore HCF, Hobday TJ, Stewart JA, Isaacs C, Salim M, Cho JK, Rinn KJ, Albain KS et al..  2015.  SWOG S0221: a phase III trial comparing chemotherapy schedules in high-risk early-stage breast cancer.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 33(1):58-64. Abstract
C
Chew HK, Barlow WE, Albain K, Lew D, Gown A, Hayes DF, Gralow JR, Hortobagyi GN, Livingston R.  2008.  A phase II study of imatinib mesylate and capecitabine in metastatic breast cancer: Southwest Oncology Group Study 0338.. Clinical breast cancer. 8(6):511-5. Abstract
G
Gralow JR, Barlow WE, Lew D, Dammann K, Somlo G, Rinn KJ, Vogel SJ, Wong L, Livingston RB, Hortobagyi GN.  2014.  A phase II study of docetaxel and vinorelbine plus filgrastim for HER-2 negative, stage IV breast cancer: SWOG S0102.. Breast cancer research and treatment. 143(2):351-8. Abstract
Gralow JR, Burstein HJ, Wood W, Hortobagyi GN, Gianni L, von Minckwitz G, Buzdar AU, Smith IE, Symmans WF, Singh B et al..  2008.  Preoperative therapy in invasive breast cancer: pathologic assessment and systemic therapy issues in operable disease.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 26(5):814-9. Abstract
H
Harigopal M, Barlow WE, Tedeschi G, Porter PL, Yeh I-T, Haskell C, Livingston R, Hortobagyi GN, Sledge G, Shapiro C et al..  2010.  Multiplexed assessment of the Southwest Oncology Group-directed Intergroup Breast Cancer Trial S9313 by AQUA shows that both high and low levels of HER2 are associated with poor outcome.. The American journal of pathology. 176(4):1639-47. Abstract
Henry LN, Hayes DF, Ramsey SD, Hortobagyi GN, Barlow WE, Gralow JR.  2014.  Promoting Quality and Evidence-Based Care in Early-Stage Breast Cancer Follow-up.. Journal of the National Cancer Institute. Abstract
Hershman DL, Unger JM, Crew KD, Minasian LM, Awad D, Moinpour CM, Hansen L, Lew DL, Greenlee H, Fehrenbacher L et al..  2013.  Randomized double-blind placebo-controlled trial of acetyl-L-carnitine for the prevention of taxane-induced neuropathy in women undergoing adjuvant breast cancer therapy.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 31(20):2627-33. Abstract
Hertz DL, Barlow WE, Kidwell KM, Albain KS, Vandenberg TA, Dakhil SR, Tirumali NR, Livingston RB, Gralow J, Hayes DF et al..  2016.  Fulvestrant decreases anastrozole drug concentrations when taken concurrently by patients with metastatic breast cancer treated on SWOG study S0226.. British journal of clinical pharmacology. Abstract
L
Lim S-O, Li C-W, Xia W, Lee H-H, Chang S-S, Shen J, Hsu JL, Raftery D, Djukovic D, Gu H et al..  2016.  EGFR signaling enhances aerobic glycolysis in triple negative breast cancer cells to promote tumor growth and immune escape.. Cancer research. 76(5):1284-1296. Abstract
M
Mehta RS, Barlow WE, Albain KS, Vandenberg TA, Dakhil SR, Tirumali NR, Lew DL, Hayes DF, Gralow JR, Livingston RB et al..  2012.  Combination anastrozole and fulvestrant in metastatic breast cancer.. The New England journal of medicine. 367(5):435-44. Abstract
Moore HCF, Unger JM, Phillips K-A, Boyle F, Hitre E, Porter D, Francis PA, Goldstein LJ, Gomez HL, Vallejos CS et al..  2015.  Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy.. The New England journal of medicine. 372(10):923-32. Abstract
R
Ramsey SD, Barlow WE, Gonzalez-Angulo AM, Tunis S, Baker L, Crowley J, Deverka P, Veenstra D, Hortobagyi GN.  2012.  Integrating comparative effectiveness design elements and endpoints into a phase III, randomized clinical trial (SWOG S1007) evaluating oncotypeDX-guided management for women with breast cancer involving lymph nodes.. Contemporary clinical trials. 34(1):1-9. Abstract
S
Schott AF, Barlow WE, Van Poznak CH, Hayes DF, Moinpour CM, Lew DL, Dy PA, Keller ET, Keller JM, Hortobagyi GN.  2016.  Phase II studies of two different schedules of dasatinib in ***bone metastasis predominant metastatic breast cancer: SWOG S0622.. Breast cancer research and treatment. Abstract
Smerage JB, Barlow WE, Hortobagyi GN, Winer EP, Leyland-Jones B, Srkalovic G, Tejwani S, Schott AF, O'Rourke MA, Lew DL et al..  2014.  Circulating Tumor Cells and Response to Chemotherapy in Metastatic Breast Cancer: SWOG S0500.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. Abstract
T
Tefferi A, Kantarjian H, Rajkumar VS, Baker LH, Abkowitz JL, Adamson JW, Advani RH, Allison J, Antman KH, Bast RC et al..  2015.  In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs.. Mayo Clinic proceedings.
Z
Zirpoli GR, Brennan PM, Hong C-C, McCann SE, Ciupak G, Davis W, Unger JM, Thomas Budd G, Hershman DL, Moore HCF et al..  2013.  Supplement use during an intergroup clinical trial for breast cancer (S0221).. Breast cancer research and treatment. 137(3):903-13. Abstract